Development of a dual-functional conjugate of antigenic peptide and Fc-III mimetics (DCAF) for targeted antibody blocking-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Development of a dual-functional conjugate of antigenic peptide and Fc-III mimetics (DCAF) for targeted antibody blocking

Published:2019 Issue:11 Volume:10 Page:3271-3280
ISSN:2041-6520
Container-title:Chemical Science
language:en
Short-container-title:Chem. Sci.

Author:

Zhang Lin¹²³⁴⁵,Shen Hao⁶⁷⁸⁹¹⁰,Gong Yiyi¹¹¹²¹³⁵¹⁴,Pang Xiaojing¹⁵¹⁶⁴⁵¹⁴,Yi Meiqi¹²³⁴⁵,Guo Lin¹²³⁴⁵,Li Jin¹²³⁴⁵,Arroyo Sam¹⁷¹⁸¹⁹¹⁰,Lu Xin¹⁷¹⁸¹⁹¹⁰,Ovchinnikov Sergey⁶⁷⁸⁹¹⁰,Cheng Gong¹⁵¹⁶⁴⁵¹⁴,Liu Xudong¹¹¹²¹³⁵¹⁴,Jiang Xu¹¹¹²¹³⁵¹⁴,Feng Shan²⁰²¹²²¹⁴,Deng Haiteng¹²³⁴⁵^ORCID

Affiliation:

1. MOE Key Laboratory of Bioinformatics

2. Center for Synthetic and Systems Biology

3. School of Life Sciences

4. Tsinghua University

5. Beijing

6. Institute for Protein Design

7. Department of Biochemistry

8. University of Washington

9. Seattle

10. USA

11. Central Research Laboratory

12. Peking Union Medical College Hospital

13. Chinese Academy of Medical Sciences and Peking Union Medical College

14. China

15. Tsinghua-Peking Center for Life Sciences

16. School of Medicine

17. Department of Biological Sciences

18. University of Notre Dame

19. South Bend

20. Mass Spectrometry Facility

21. Westlake Lake University

22. Hangzhou

Abstract

Long peptide DCAF enables high selectivity to target harmful antibodies, providing new thoughts for antibody-induced disease intervention.

Funder

Tsinghua University

National Natural Science Foundation of China

Publisher

Royal Society of Chemistry (RSC)

Subject

General Chemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2019/SC/C8SC05273E

Reference38 articles.

1. Paul Ehrlich's magic bullet concept: 100 years of progress

2. Strategies and challenges for the next generation of antibody–drug conjugates

3. Antibody-Drug Conjugates: An Emerging Concept in Cancer Therapy

4. Antibody–drug conjugates

5. How some T cells escape tolerance induction

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preparation of trastuzumab-DM1 conjugate with a high drug-to-antibody ratio for breast cancer therapy;Nano Today;2024-02

2. Preparation of an Ultrahigh-DAR PDL1 monoclonal antibody-polymeric-SN38 conjugate for precise colon cancer therapy;Biomaterials;2023-10

3. Application of Computational Techniques in Antibody Fc-Fused Molecule Design for Therapeutics;Molecular Biotechnology;2023-09-24

4. Boosting the specific molecular recognition of β-amyloid oligomer by constructing of antibody-mimic Y probe;Sensors and Actuators B: Chemical;2023-04

5. Photoresponsive liposomes: an alternative of ELISA for the detection of low quantities of target substances;Pharmaceutical Patent Analyst;2023-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3